Create Free Account

By creating account you will get access to hot stocks & personalised emails

Chimeric Therapeutics Ltd

Healthcare AU CHM

0.006AUD
-0.001(14.29%)

Last update at 2024-12-19T05:11:00Z

Day Range

0.0060.007
LowHigh

52 Week Range

0.0060.04
LowHigh

Fundamentals

  • Previous Close 0.007
  • Market Cap9.45M
  • Volume4139804
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-12.17948M
  • Revenue TTM7.46M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM 4.51M
  • Diluted EPS TTM-0.02

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Income before tax -25.40756M -14.45995M -15.11371M -0.06401M
Minority interest - - - -
Net income -25.50038M -14.62367M -15.11371M -0.06401M
Selling general administrative 14.88M 8.73M 5.82M 0.06M
Selling and marketing expenses - - 0.15M -
Gross profit - - 0.00265M -
Reconciled depreciation 0.97M 0.95M 0.00263M -
Ebit -24.98147M -13.81776M -15.10783M -0.15362M
Ebitda -23.66837M -12.86800M -15.10520M -
Depreciation and amortization - 0.95M 0.00263M -
Non operating income net other - - - -
Operating income -25.40756M -13.81776M -15.10783M -0.06401M
Other operating expenses - 17.19M 14.85M 3.50M
Interest expense 0.85M 0.64M 0.00588M 0.00000M
Tax provision 0.09M 0.16M 0.00000M 0.00000M
Interest income 0.03M 0.01M 0.00265M -
Net interest income -0.74628M -0.62715M -0.00588M -
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 0.09M 0.16M -0.25791M -
Total revenue 0.00000M 0.00000M 0.00265M 0.00000M
Total operating expenses - 17.19M 14.85M -
Cost of revenue - - - -
Total other income expense net 4.83M 3.36M -0.26379M -
Discontinued operations - - - -
Net income from continuing ops -25.50038M -14.62367M -15.11371M -
Net income applicable to common shares -25.91689M -15.89840M -15.11371M -0.15362M
Preferred stock and other adjustments - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 15.27M 22.49M 34.88M 36.50M 0.00010M
Intangible assets - 12.98M 13.65M 13.83M -
Earning assets - - - - -
Other current assets 0.08M 0.33M 0.13M 0.23M -
Total liab 12.80M 16.41M 9.17M 11.37M 0.06M
Total stockholder equity 2.47M 6.08M 25.71M 25.13M -0.06391M
Deferred long term liab - - - - -
Other current liab 6.90M 3.52M 4.32M 5.32M -
Common stock 63.51M 53.93M 51.81M 37.37M 0.00010M
Capital stock - 53.93M 51.81M 37.37M -
Retained earnings -66.55956M -56.78081M -29.58920M -15.17772M -0.06401M
Other liab - 2.02M 0.15M 4.02M -
Good will - - - - -
Other assets - - 0.04M - -
Cash 3.05M 2.36M 18.38M 22.41M 0.00010M
Cash and equivalents - - 18.38M 22.41M -
Total current liabilities 10.10M 14.69M 9.02M 7.35M 0.06M
Current deferred revenue - - - - -
Net debt -3.05300M - -18.38153M -22.41020M -
Short term debt - - 0.00000M 0.00000M 0.03M
Short long term debt - - - - -
Short long term debt total - - - 3.68M -
Other stockholder equity - 8.51M -0.87866M 2.94M -
Property plant equipment - 0.00560M 0.02M 0.01M -
Total current assets 3.22M 9.35M 21.17M 22.67M 0.00010M
Long term investments - 0.04M 0.04M - -
Net tangible assets - -7.31792M 12.05M 11.30M -0.06391M
Short term investments - - - - -
Net receivables 0.09M 3.65M 3.54M 0.02M -
Long term debt - - 0.00000M 3.68M -
Inventory - - -0.88213M - -
Accounts payable 3.20M 7.41M 4.70M 2.04M -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 5.52M - 4.37M 2.94M -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 12.05M - - - -
Deferred long term asset charges - - - - -
Non current assets total 12.05M 13.02M 13.71M 13.84M -
Capital lease obligations - - - - -
Long term debt total - - 0.00000M 3.68M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Investments -0.11219M -0.04000M -0.04000M -0.04000M
Change to liabilities 4.74M 0.32M 2.59M 0.07M
Total cashflows from investing activities -0.11219M -0.57786M -5.30704M -5.30704M
Net borrowings -2.22500M -4.04682M -0.03401M 0.08M
Total cash from financing activities 0.25M 9.50M 36.54M 0.08M
Change to operating activities 0.10M 0.10M -0.23062M -0.23062M
Net income -25.91689M -15.89840M -15.11371M -0.15362M
Change in cash -16.01888M -4.02867M 22.41M 0.00024M
Begin period cash flow 18.38M 22.41M 0.00010M -
End period cash flow 2.36M 18.38M 22.41M 0.00010M
Total cash from operating activities -16.30575M -13.15289M -8.83273M -0.08162M
Issuance of capital stock 2.58M 14.90M 39.30M -
Depreciation 0.97M 0.95M 0.85M 0.85M
Other cashflows from investing activities 0.00000M 0.01M 0.00265M 0.00265M
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables -0.99337M -2.63352M -0.02425M -0.02425M
Sale purchase of stock 2.58M -1.30866M -2.71505M 0.00010M
Other cashflows from financing activities -0.09912M -0.56488M 0.85M -2.72463M
Change to netincome 4.80M 4.01M 3.10M 3.10M
Capital expenditures 0.11M 0.54M 5.31M 0.02M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital 3.53M -0.00342M - -
Stock based compensation - - - -
Other non cash items - - - -
Free cash flow -16.41795M -0.53785M -5.30704M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CHM
Chimeric Therapeutics Ltd		 -0.001 14.29% 0.006 - - 1.27 4.46 8325.14 -2.1391
CSL
CSL Ltd		 -3.45 1.22% 278.79 32.86 33.00 9.11 5.02 6.65 20.64
TLX
Telix Pharmaceuticals Ltd		 -0.07 0.27% 25.67 161.73 75.19 12.58 19.98 12.52 109.28
MSB
Mesoblast Ltd		 1.07 54.04% 3.05 - 454.55 312.43 2.49 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.36 2.79% 12.54 13.51 35.21 8.91 5.13 6.48 8.45

Reports Covered

Stock Research & News

View All

Profile

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17 CAR T cell therapy that is in Phase I/II multi-centre clinical trials for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a Chlorotoxin CAR T cell therapy, which is in phase Ia/IIb clinical trials for patients with recurrent or progressive Glioblastoma, as well as in preclinical trials for MMP2 expressing solid tumors. It also develops CHM CORE-NK that is in phase Ia/IIb clinical trials for acute myeloid leukaemia/colorectal cancer and acute myeloid cancer, as well as in preclinical trials for blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.

Chimeric Therapeutics Ltd

62 Lygon Street, Carlton, VIC, Australia, 3053

Key Executives

Name Title Year Born
Ms. Jennifer Chow CEO, MD & Director NA
Mr. Eliot Bourk Chief Bus. Officer & Head of External Innovation NA
Dr. Li Ren VP of Technical Operations NA
Mr. Kelly R. Thornburg VP & Head of Quality 1963
Mr. Jason B. Litten M.D. Chief Medical Officer 1974
Mr. Phillip Hains B Bus, C.A., CA, M.B.A., MBA Sec. 1961
Mr. Nathan Jong C.A. Company Sec. NA
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD Founder & Executive Chairman 1956
Mr. Eliot Bourk Chief Business Officer & Head of External Innovation NA
Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A. CFO, Joint Company Secretary & Director 1959

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.